Uroviva Klinik AG

Based in Switzerland, Uroviva Klinik AG offers specialized urological healthcare services focusing on diagnosis and treatment of urinary tract and male reproductive organ conditions. Uroviva Klinik AG, founded in 2004, operates in Bulach, Switzerland, providing dedicated urological care. The company has completed 2 funding deals, with the latest round on March 1, 2025. Med Gablinger is recognized as the founder, and the current CEO is Jan Sobhani.

Uroviva specializes in urological healthcare, providing a comprehensive range of services centered on the diagnosis and treatment of conditions affecting the urinary tract and male reproductive organs. Their core offerings include outpatient consultations, specialized surgical procedures, and comprehensive treatment plans for various urological diseases, including bladder cancer and prostate disorders. Uroviva operates a network consisting of a specialized urology clinic and multiple outpatient practices across Switzerland, serving a diverse patient demographic that includes both men and women. The company's services are designed for immediate accessibility, with extended operational hours, including Saturday appointments, to accommodate patient needs.

Uroviva's geographical footprint extends throughout Switzerland, particularly in urban areas such as Zurich and Bülach, ensuring that specialized urological care is readily available to a wide patient base. Uroviva generates revenue primarily through patient consultations and urological procedures, structured around direct interactions with patients and referrals from general practitioners. The company operates on a fee-for-service model, where patients are billed for consultations, surgeries, and additional diagnostic services. Revenue streams are derived from both individual patients and partnerships with healthcare providers, ensuring a steady flow of clients needing urological care.

Given the specialized nature of their services, Uroviva engages in premium pricing strategies, reflecting the advanced medical expertise and comprehensive care provided. The organization’s revenue is bolstered through a high volume of annual consultations and surgical operations, highlighting its position as a significant provider in the urological healthcare sector in Switzerland. In March 2025, Uroviva Klinik AG was acquired by Affidea B. V.

, a portfolio company of Groupe Bruxelles Lambert. This acquisition is positioned to expand and accelerate their next phase of growth. Future plans include the development and launch of new urological treatments, with anticipated releases aimed at addressing emerging healthcare needs. Additionally, Uroviva aims to extend its services to new geographic regions across Switzerland, enhancing access to specialized care.

The strategic acquisition and upcoming initiatives will leverage Affidea's resources to support these growth objectives.